2024
Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Streiff M, Holmstrom B, Angelini D, Ashrani A, Buckner T, Diep R, Fertrin K, Fogerty A, Crestani N, Gangaraju R, Rojas-Hernandez C, Goldhaber S, Ibrahim I, Kubal T, Leavitt A, Lim M, Mann J, Mantha S, Morton C, Nester A, O'Brien A, Ortel T, Pine A, Pishko A, Ranade M, Salmasi A, Schaefer J, Williams E, Wool G, Wun T, Montgomery S, Nguyen J, Freedman-Cass D, Sliker B. Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22: 483-506. PMID: 39236759, DOI: 10.6004/jnccn.2024.0046.Peer-Reviewed Original ResearchConceptsNCCN Clinical Practice GuidelinesNCCN GuidelinesClinical practice guidelinesVenous thromboembolismVenous thromboembolic diseaseNCCN panelCancer-associated venous thromboembolismInternal medicinePractice guidelinesMedical oncologyThromboembolic diseaseTreatment of venous thromboembolismNCCNLife-threatening conditionMultidisciplinary effortRecommended treatment optionGuidelinesOncologyAdult patientsTreatment optionsInterventional radiologyDiverse subtypesCancerPatientsPrevention
2023
The Choice of Anticoagulant at First Recurrence Does Not Alter the Risk for the Second Recurrence
Muradashvili T, Restrepo V, Alameddine D, Soliman S, Feinn R, Chaar C, Lee A, Pine A. The Choice of Anticoagulant at First Recurrence Does Not Alter the Risk for the Second Recurrence. Blood 2023, 142: 5540. DOI: 10.1182/blood-2023-191084.Peer-Reviewed Original ResearchFirst VTE recurrenceDeep venous thrombosisFirst venous thromboembolismRecurrent VTE eventsVTE recurrenceVenous thromboembolismPulmonary embolismAnticoagulation regimenVTE eventsAnticoagulant regimenFirst recurrenceINR targetSecond recurrenceExact testFirst recurrent venous thromboembolismInferior vena cava atresiaLarge tertiary academic hospitalUnprovoked first venous thromboembolismMajor public health hazardDifferent anticoagulant agentsInterruption of anticoagulationCardiovascular risk factorsMay-Thurner syndromePatients 18 yearsRecurrent venous thromboembolism
2021
Proteomic Profiles in Patients with Thrombosis Due to COVID-19 Are Distinct from Non-COVID-19 Thrombosis
Madeeva D, Borges K, Shallow M, Juthani P, Wang S, Gupta A, Chun H, Lee A, Pine A. Proteomic Profiles in Patients with Thrombosis Due to COVID-19 Are Distinct from Non-COVID-19 Thrombosis. Blood 2021, 138: 777. PMCID: PMC8701622, DOI: 10.1182/blood-2021-153959.Peer-Reviewed Original ResearchSerum amyloid ACOVID-19 patientsVenous thromboembolismCOVID-19 infectionLipocalin-2Thromboembolic eventsThromboembolic complicationsPentraxin 3Complement factors C2COVID-19Lower extremity Doppler ultrasoundTissue factorComplement activationCell adhesion molecule-1Pathogenesis of thromboembolismInstitutional review board approvalChest CT angiographyAdhesion molecule-1Endothelial cell adhesion molecule-1Novel therapeutic strategiesSodium citrate tubesReview board approvalClassical complement pathwayRadiologic confirmationICU patients